Thermo Fisher Scientific will showcase its innovations and expertise in pharmaceutical services at CPHI Frankfurt 2022.

[ad_1]

FRANKFURT, Germany–(BUSINESS WIRE)–This week at CPHI Frankfurt, Thermo Fisher Scientific will showcase its expertise, innovation and capabilities to help pharmaceutical and emerging biotech companies accelerate time to market across a wide range of modalities and platforms, including cell and gene therapies, oral solids, steriles. and biological. Thermo Fisher experts at CPHI Frankfurt 2022, November 1-3, 2022, booth #90J10, hall 9.

“As pharma and biotechs strive to turn molecules into medicines, they are looking for integrated solutions that connect the entire value chain, from early development and clinical trials to scalable manufacturing and integrated sourcing,” said Leon Wyszkowski, president of commercial operations, Pharmaceutical Services. Thermo Fisher Scientific. “This week, we’re showcasing our deep expertise across a range of topics, from clinical research and advanced therapies to digital technologies, to help our customers accelerate their innovation and accelerate the delivery of breakthrough medicines and therapies to patients.”

CPHI Frankfurt expert live sessions

On November 1 and 2, Thermo Fisher experts will be participating in several sessions, including:

Keynote: Delivering on the promise of cell and gene therapy, a patient-centered approachPanteli Theocharous, Ph.D., FRCPath, Global Vice President, Cell and Gene Therapy Strategy Lead, Clinical Research, Thermo Fisher, November 1, 14:00-14:30 CET

The impact of M&A on the pharma and CDMO community, Anil Kane, Ph.D., Global Head of Technical and Scientific Affairs, Pharma Services, Thermo Fisher November 1, 2.40-3.30pm CET

Providing a digital culture through integrated business processes, Sarah Sheriff, VP Integration/Engineering Operations, Pharma Services, Thermo Fisher November 2, 11:20 – 11:45 CET

For more information on Thermo Fisher sessions and events at CPHl Frankfurt, visit here.

Enabling Innovation for Advanced Therapies

Thermo Fisher continues to expand its capabilities to enable the delivery of cell and gene therapies to customers. New viral vector production Recently opened in Plainville, Massachusetts to support the development, testing and production of complex viral vectors. The state-of-the-art 300,000-square-foot facility features sustainable building design, flexible laboratory and manufacturing suites, adjacent warehouse and office space, and Thermo Fisher’s advanced biomanufacturing and analytical instrumentation technologies.

New Rapid access to the clinic for the viral vector an all-in-one manufacturing platform that utilizes IND-ready platform processes optimized for lentivirus and AAV production to help eliminate regulatory risk and accelerate the path to the clinic. Also new Patheon’s commercial packaging services for cell and gene therapy integrate GMP storage, batching, ultra-cold and cryogenic packaging and global distribution to meet specific needs to ensure supply chain integrity. To support customers in early stage development, Thermo Fisher has opened two new translational sciences laboratories in San Diego, California and Alachua, Florida, allowing proof-of-concept research to seamlessly transition into preclinical research and accelerate commercialization. Finally, a new one Rapid care for advanced therapy Delivers an improved customer experience by streamlining contracts, communications and coordination between all aspects of the value chain when contracting for two or more services in an advanced therapy portfolio.

In addition, a new cell therapy development and cGMP manufacturing center will open next year at the University of California, San Francisco’s Mission Bay campus, providing customers with comprehensive solutions to reduce costs and accelerate the adoption of cell therapy.

Expansion of sterile and biological capabilities

The company has expanded its capabilities to support the global demand for the production of sterile materials and biologics. At the end of this year, the company will open its new production facility Hangzhou, Chinait offers combined biological drug substance and sterile drug product capabilities.

Thermo Fisher is expanding opportunities for the production of biological drugs To support production growth at the 2KL and 5KL scale, its St. Louis, Mo. The 5KL single-use bioreactor platform was launched through work at the site’s Bioprocessing Collaboration Center, which is designed to bring together the expertise of the company’s biomanufacturing and pharmaceutical services businesses to develop new bioprocessing technologies and workflows. With a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, and extensive stainless steel manufacturing processes with future one-time capacity investments, Thermo Fisher provides maximum flexibility in product development and commercialization. launch.

Digital transformation of the supply chain

The company continues to use new digital technologies across its pharmaceutical services network to optimize production efficiency, streamline processes and improve customer engagement. New features include implementation Pharma 4.0 Coordinate and integrate data and drive digital transformation at all stages of drug development and manufacturing. In addition, the company’s new mysupply is a digital supply chain platform provides customers with visibility across the full product lifecycle, including daily order management, batch tracking and monthly forecasting.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is a world leader in science services with annual revenues of approximately $40 billion. Our mission is to empower our customers to make the world healthier, cleaner and safer. We are ready to support our customers whether they are accelerating life sciences research, solving complex analytical problems, increasing productivity in laboratories, improving patient health through diagnostics, or developing and manufacturing life-changing therapies. Our global team offers an unmatched combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, visit www.thermofisher.com.